{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:22:00Z","timestamp":1708474920981},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,20]]},"DOI":"10.7759\/cureus.54533","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:59:25Z","timestamp":1708437565000},"source":"Crossref","is-referenced-by-count":0,"title":["Extended-Spectrum Beta-Lactamase Escherichia coli-Associated Acute Cholangitis: Uncommon Patient Characteristics and Clinical Implications"],"prefix":"10.7759","author":[{"given":"Somin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alemam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misbahuddin","family":"Khaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Dev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2018.11.002","article-title":"Cholangitis: causes, diagnosis, and management","volume":"99","author":"Sulzer JK","year":"2019","unstructured":"Sulzer JK, Ocuin LM. Cholangitis: causes, diagnosis, and management. Surg Clin North Am. 2019, 99:175-84. 10.1016\/j.suc.2018.11.002","journal-title":"Surg Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.452","article-title":"Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis","volume":"24","author":"Gomi H","year":"2017","unstructured":"Gomi H, Takada T, Hwang TL, et al.. Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepatobiliary Pancreat Sci. 2017, 24:310-8. 10.1002\/jhbp.452","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2012.45.2.155","article-title":"Extended spectrum-\u03b2-lactamase or carbapenemase producing bacteria isolated from patients with acute cholangitis","volume":"45","author":"Goo JC","year":"2012","unstructured":"Goo JC, Seong MH, Shim YK, et al.. Extended spectrum-\u03b2-lactamase or carbapenemase producing bacteria isolated from patients with acute cholangitis. Clin Endosc. 2012, 45:155-60. 10.5946\/ce.2012.45.2.155","journal-title":"Clin Endosc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.509","article-title":"Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis","volume":"25","author":"Miura F","year":"2018","unstructured":"Miura F, Okamoto K, Takada T, et al.. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018, 25:31-40. 10.1002\/jhbp.509","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01201-6","article-title":"Use of microbiological and patient data for choice of empirical antibiotic therapy in acute cholangitis","volume":"20","author":"Kruis T","year":"2020","unstructured":"Kruis T, G\u00fcse-Jaschuck S, Siegmund B, Adam T, Epple HJ. Use of microbiological and patient data for choice of empirical antibiotic therapy in acute cholangitis. BMC Gastroenterol. 2020, 20:65. 10.1186\/s12876-020-01201-6","journal-title":"BMC Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-012-0566-y","article-title":"TG13: updated Tokyo Guidelines for the management of acute cholangitis and cholecystitis","volume":"20","author":"Takada T","year":"2013","unstructured":"Takada T, Strasberg SM, Solomkin JS, et al.. TG13: updated Tokyo Guidelines for the management of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013, 20:1-7. 10.1007\/s00534-012-0566-y","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.2169","article-title":"Review of the Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis","volume":"154","author":"Buckman SA","year":"2019","unstructured":"Buckman SA, Mazuski JE. Review of the Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. JAMA Surg. 2019, 154:873-4. 10.1001\/jamasurg.2019.2169","journal-title":"JAMA Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviscsurg.2019.05.007","article-title":"Acute cholangitis: diagnosis and management","volume":"156","author":"Sokal A","year":"2019","unstructured":"Sokal A, Sauvanet A, Fantin B, de Lastours V. Acute cholangitis: diagnosis and management. J Visc Surg. 2019, 156:515-25. 10.1016\/j.jviscsurg.2019.05.007","journal-title":"J Visc Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.129802","article-title":"Clinicomicrobiological analysis of patients with cholangitis","volume":"32","author":"Shenoy SM","year":"2014","unstructured":"Shenoy SM, Shenoy S, Gopal S, Tantry BV, Baliga S, Jain A. Clinicomicrobiological analysis of patients with cholangitis. Indian J Med Microbiol. 2014, 32:157-60. 10.4103\/0255-0857.129802","journal-title":"Indian J Med Microbiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris PN","year":"2018","unstructured":"Harris PN, Tambyah PA, Lye DC, et al.. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018, 320:984-94. 10.1001\/jama.2018.12163","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.3.1089-1094.2004","article-title":"Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients","volume":"42","author":"Rodr\u00edguez-Ba\u00f1o J","year":"2004","unstructured":"Rodr\u00edguez-Ba\u00f1o J, Navarro MD, Romero L, et al.. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004, 42:1089-94. 10.1128\/JCM.42.3.1089-1094.2004","journal-title":"J Clin Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0401-6","article-title":"Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"27","author":"Kang CI","year":"2008","unstructured":"Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, Choe KW. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2008, 27:85-8. 10.1007\/s10096-007-0401-6","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/228475-extended-spectrum-beta-lactamase-escherichia-coli-associated-acute-cholangitis-uncommon-patient-characteristics-and-clinical-implications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:59:28Z","timestamp":1708437568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/228475-extended-spectrum-beta-lactamase-escherichia-coli-associated-acute-cholangitis-uncommon-patient-characteristics-and-clinical-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.54533","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}